BCSG1基因在乳腺癌新辅助化疗疗效评估中的价值  

The value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy for breast cancer

作　　者：何劲松[1] 袁建辉[2] 王先明[1] 郭良峰[1] 朱国献[1] 伍健春[1] 李戎[1] 王敏[1] 陈伟财[1] 吴恢升[1] 

机构地区：[1]广东省深圳市第二人民医院乳腺疾病诊疗中心,广东深圳518035 [2]广东省深圳市疾病预防控制中心,广东深圳518020

出　　处：《中国普通外科杂志》2007年第8期793-796,共4页China Journal of General Surgery

基　　金：广东省深圳市科技计划资助项目(200404082)

摘　　要：目的探讨乳腺癌特异基因(BCSG1)在乳腺癌新辅助化疗疗效评估中的价值。方法采用免疫组化S-P法和荧光定量PCR方法检测36例乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达,比较化疗前后肿瘤体积的变化情况,分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果36例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小(P<0.01),病灶缓解率(CR+PR)为85.6%;新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前(P<0.05),BCSG1蛋白高表达率低于新辅助化疗前(P<0.01)。结论乳腺癌新辅助化疗后BCSG1在分子和蛋白水平表达均明显降低,与新辅助化疗后疗效呈负相关(r=-0.539,P<0.01),提示BCSG1可作为乳腺癌新辅助化疗疗效的预测因子。Objective To study the value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy （ NC ） for breast cancer. Methods The expression of BCSG 1 in cancer tissue was assayed by immunohistochemistry and RT-PCR in 36 cases of breast cancer patients before and after receiving NC of CEF （cyclophosphamide, epirubicin and fluorouracil ） regimen. The therapeutic response of NC was evaluated by morphological and pathological observation. The relationship between expression of BCSG 1 and morphological response to NC was analyzed. Results Among the studied cases, the diameter of tumor significantly decreased（P 〈 0. 01 ） and the improvment rate of the treatment effect （ CR ＋ PR） was 85. 6%. The expression of BCSG1 mRNA （ P 〈 0.05 ） and the high expression rate of BCSG1 （ P 〈 0.01 ） were decreased significantly after receiving blC than that before NC. Conclusions After NC, the expression of BCSG 1 mRNA and protein was decreased significantly, which had negative relation to the therapeutic effect of NC. BCSG 1 can be a prognosticate gene to evaluate the effect of NC in breast cancer patients.

关 键 词：乳腺肿瘤 乳腺癌特异基因(BCSG1) 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]